Sold as Actidil. Every FDA application for this active ingredient: 2 branded and 6 generic.
As of Nov 15, 2026, FDA lists 8 applications for Triprolidine Hydrochloride (sold as Actidil), with 0 new uses approved and 0 published complete response letters.
| Feb 7, 1977 | Triprolidine HydrochlorideANDA 85094 | Watson Labs | 0 | Discontinued |
| Jul 13, 1979 | Triprolidine HydrochlorideANDA 85940 | Alpharma US Pharms | 9 | Discontinued |
| Jan 18, 1983 | MyidylANDA 87963 | Usl Pharma | 7 | Discontinued |
| Jan 17, 1985 | Triprolidine HydrochlorideANDA 88735 | Halsey | 0 | Discontinued |
| — | Triprolidine HydrochlorideANDA 85610 | Vitarine | 0 | Discontinued |
| — | Triprolidine HydrochlorideANDA 87514 | Pharm Assoc | 0 | Discontinued |
| — | ActidilNDA 11110 | Glaxosmithkline | 0 | Discontinued |
| — | ActidilNDA 11496 | Glaxosmithkline | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Glaxosmithkline